158 related articles for article (PubMed ID: 21933891)
1. Therapeutic implications for the induced levels of Chk1 in Myc-expressing cancer cells.
Höglund A; Nilsson LM; Muralidharan SV; Hasvold LA; Merta P; Rudelius M; Nikolova V; Keller U; Nilsson JA
Clin Cancer Res; 2011 Nov; 17(22):7067-79. PubMed ID: 21933891
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells.
Ferrao PT; Bukczynska EP; Johnstone RW; McArthur GA
Oncogene; 2012 Mar; 31(13):1661-72. PubMed ID: 21841818
[TBL] [Abstract][Full Text] [Related]
3. Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma.
Derenzini E; Agostinelli C; Imbrogno E; Iacobucci I; Casadei B; Brighenti E; Righi S; Fuligni F; Ghelli Luserna Di Rorà A; Ferrari A; Martinelli G; Pileri S; Zinzani PL
Oncotarget; 2015 Mar; 6(9):6553-69. PubMed ID: 25544753
[TBL] [Abstract][Full Text] [Related]
4. The checkpoint 1 kinase inhibitor LY2603618 induces cell cycle arrest, DNA damage response and autophagy in cancer cells.
Wang FZ; Fei HR; Cui YJ; Sun YK; Li ZM; Wang XY; Yang XY; Zhang JG; Sun BL
Apoptosis; 2014 Sep; 19(9):1389-98. PubMed ID: 24928205
[TBL] [Abstract][Full Text] [Related]
5. Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-Dependent Cell Death in T-cell and Hodgkin Lymphoma.
Ravi D; Beheshti A; Abermil N; Passero F; Sharma J; Coyle M; Kritharis A; Kandela I; Hlatky L; Sitkovsky MV; Mazar A; Gartenhaus RB; Evens AM
Cancer Res; 2016 Jun; 76(11):3319-31. PubMed ID: 26988986
[TBL] [Abstract][Full Text] [Related]
6. Synergistic targeting of CHK1 and mTOR in MYC-driven tumors.
Song X; Wang L; Wang T; Hu J; Wang J; Tu R; Su H; Jiang J; Qing G; Liu H
Carcinogenesis; 2021 Apr; 42(3):448-460. PubMed ID: 33206174
[TBL] [Abstract][Full Text] [Related]
7. ATM promotes apoptosis and suppresses tumorigenesis in response to Myc.
Pusapati RV; Rounbehler RJ; Hong S; Powers JT; Yan M; Kiguchi K; McArthur MJ; Wong PK; Johnson DG
Proc Natl Acad Sci U S A; 2006 Jan; 103(5):1446-51. PubMed ID: 16432227
[TBL] [Abstract][Full Text] [Related]
8. MYC regulation of CHK1 and CHK2 promotes radioresistance in a stem cell-like population of nasopharyngeal carcinoma cells.
Wang WJ; Wu SP; Liu JB; Shi YS; Huang X; Zhang QB; Yao KT
Cancer Res; 2013 Feb; 73(3):1219-31. PubMed ID: 23269272
[TBL] [Abstract][Full Text] [Related]
9. Chk2 deficiency in Myc overexpressing lymphoma cells elicits a synergistic lethal response in combination with PARP inhibition.
Höglund A; Strömvall K; Li Y; Forshell LP; Nilsson JA
Cell Cycle; 2011 Oct; 10(20):3598-607. PubMed ID: 22030621
[TBL] [Abstract][Full Text] [Related]
10. Up-regulation of the PI3K/AKT and RHO/RAC/PAK signalling pathways in CHK1 inhibitor resistant Eµ-Myc lymphoma cells.
Hunter JE; Campbell AE; Kerridge S; Fraser C; Hannaway NL; Luli S; Ivanova I; Brownridge PJ; Coxhead J; Taylor L; Leary P; Hasoon MSR; Eyers CE; Perkins ND
Biochem J; 2022 Oct; 479(19):2131-2151. PubMed ID: 36240067
[TBL] [Abstract][Full Text] [Related]
11. RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma.
Cole KA; Huggins J; Laquaglia M; Hulderman CE; Russell MR; Bosse K; Diskin SJ; Attiyeh EF; Sennett R; Norris G; Laudenslager M; Wood AC; Mayes PA; Jagannathan J; Winter C; Mosse YP; Maris JM
Proc Natl Acad Sci U S A; 2011 Feb; 108(8):3336-41. PubMed ID: 21289283
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of AP-1 transcription activator induces myc-dependent apoptosis in HL60 cells.
Park S; Hahm ER; Lee DK; Yang CH
J Cell Biochem; 2004 Apr; 91(5):973-86. PubMed ID: 15034932
[TBL] [Abstract][Full Text] [Related]
13. Small molecule inhibitors and a kinase-dead expressing mouse model demonstrate that the kinase activity of Chk1 is essential for mouse embryos and cancer cells.
Muralidharan SV; Nilsson LM; Lindberg MF; Nilsson JA
Life Sci Alliance; 2020 Aug; 3(8):. PubMed ID: 32571801
[TBL] [Abstract][Full Text] [Related]
14. AKT signalling is required for ribosomal RNA synthesis and progression of Eμ-Myc B-cell lymphoma in vivo.
Devlin JR; Hannan KM; Ng PY; Bywater MJ; Shortt J; Cullinane C; McArthur GA; Johnstone RW; Hannan RD; Pearson RB
FEBS J; 2013 Nov; 280(21):5307-16. PubMed ID: 23331925
[TBL] [Abstract][Full Text] [Related]
15. CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo.
Tse AN; Rendahl KG; Sheikh T; Cheema H; Aardalen K; Embry M; Ma S; Moler EJ; Ni ZJ; Lopes de Menezes DE; Hibner B; Gesner TG; Schwartz GK
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):591-602. PubMed ID: 17255282
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of CHK1 and WEE1 as a new therapeutic approach in diffuse large B cell lymphomas with MYC deregulation.
Restelli V; Vagni M; Arribas AJ; Bertoni F; Damia G; Carrassa L
Br J Haematol; 2018 Apr; 181(1):129-133. PubMed ID: 28025833
[No Abstract] [Full Text] [Related]
17. Inhibition of checkpoint kinase 1 abrogates G2/M checkpoint activation and promotes apoptosis under heat stress.
Furusawa Y; Iizumi T; Fujiwara Y; Zhao QL; Tabuchi Y; Nomura T; Kondo T
Apoptosis; 2012 Jan; 17(1):102-12. PubMed ID: 22080164
[TBL] [Abstract][Full Text] [Related]
18. Impaired ribosome biogenesis checkpoint activation induces p53-dependent MCL-1 degradation and MYC-driven lymphoma death.
Domostegui A; Peddigari S; Mercer CA; Iannizzotto F; Rodriguez ML; Garcia-Cajide M; Amador V; Diepstraten ST; Kelly GL; Salazar R; Kozma SC; Kusnadi EP; Kang J; Gentilella A; Pearson RB; Thomas G; Pelletier J
Blood; 2021 Jun; 137(24):3351-3364. PubMed ID: 33512431
[TBL] [Abstract][Full Text] [Related]
19. Regulation of CHK1 inhibitor resistance by a c-Rel and USP1 dependent pathway.
Hunter JE; Campbell AE; Hannaway NL; Kerridge S; Luli S; Butterworth JA; Sellier H; Mukherjee R; Dhillon N; Sudhindar PD; Shukla R; Brownridge PJ; Bell HL; Coxhead J; Taylor L; Leary P; Hasoon MSR; Collins I; Garrett MD; Eyers CE; Perkins ND
Biochem J; 2022 Oct; 479(19):2063-2086. PubMed ID: 36240066
[TBL] [Abstract][Full Text] [Related]
20. Ultrasound activates ataxia telangiectasia mutated- and rad3-related (ATR)-checkpoint kinase 1 (Chk1) pathway in human leukemia Jurkat cells.
Furusawa Y; Iizumi T; Fujiwara Y; Hassan MA; Tabuchi Y; Nomura T; Kondo T
Ultrason Sonochem; 2012 Nov; 19(6):1246-51. PubMed ID: 22571845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
